PIK3CA and neoplasm: These different approaches demonstrated that pan-PI3K/mTOR inhibition by gedatolisib generally exerted more potent and efficacious anti-proliferative/cytotoxic effects than single-node PAM inhibitors, regardless of the tumor cells’ PAM pathway mutational status.